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Abstract
Background: We systematically reviewed the comparative effectiveness of injectable beta-interferons (IFN-β) and
glatiramer acetate (GA) on annualised relapse rate (ARR), progression and discontinuation due to adverse events
(AEs) in RRMS, using evidence from within the drugs’ recommended dosages.
Methods: We updated prior comprehensive reviews, checked references of included studies, contacted experts in
the field, and screened websites for relevant publications to locate randomised trials of IFN-β and GA with
recommended dosages in RRMS populations, compared against placebo or other recommended dosages. Abstracts
were screened and assessed for inclusion in duplicate and independently. Studies were appraised using the
Cochrane risk of bias tool. Rate ratios for ARR, hazard ratios for time to progression, and risk ratios for
discontinuation due to AEs were synthesised in separate models using random effects network meta-analysis.
Results: We identified 24 studies reported in 42 publications. Most studies were at high risk of bias in at least one
domain. All drugs had a beneficial effect on ARR as compared to placebo, but not compared to each other, and
findings were robust to sensitivity analysis. We considered time to progression confirmed at 3 months and confirmed
at 6 months in separate models; while both models suggested that the included drugs were effective, findings were
not consistent between models. Discontinuation due to AEs did not appear to be different between drugs.
Conclusions: Meta-analyses confirmed that IFN-β and GA reduce ARR and generally delay progression as defined in
these trials, though there was no clear ‘winner’ across outcomes. Findings are additionally tempered by the high risk of
bias across studies, and the use of an impairment/mobility scale to measure disease progression. Future research
should consider more relevant measures of disability and, given that most trials have been short-term, consider a
longitudinal approach to comparative effectiveness.
Review registration: PROSPERO CRD42016043278.
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Background
Injectable beta-interferons (IFN-β) and glatiramer acet-
ate (GA) are mainstays of first-line treatment for
relapsing-remitting multiple sclerosis (RRMS), with the
primary goals of reducing the rate of relapses and delay-
ing disease progression. Newer therapies such as alemtu-
zumab yield greater effects in reducing relapse rate and
slowing disease progression, and patients may prefer
therapies such as dimethyl fumarate or teriflunomide
because of their oral mode of administration. However,
amongst other disease-modifying therapies (DMTs),
IFN-β and GA both have well-established long-term
safety profiles without the severe side effects presented
by other drugs. While IFN-β and GA are not appropriate
for aggressive forms of RRMS (i.e. highly active RRMS
or rapidly evolving-severe RRMS), the Association of
British Neurologists (ABN) classifies these as ‘drugs of
moderate efficacy’ [1]. Beginning in 2017, an appraisal
committee of the UK National Institute for Health and
Care Excellence received evidence as part of its recon-
sideration of the clinical and cost effectiveness of IFN-β
and GA for use in the UK National Health Service. The
work presented here, the full record of which can be
found at [2], draws from our report to this appraisal
committee.
There are currently five licensed IFN-β drugs indicated
for RRMS. These include: two IFN β-1a (Avonex® (Bio-
gen, Cambridge, Massachusetts, USA), administered via
intramuscular injection once weekly at a dose of 30 μg;
and Rebif® (Merck, Darmstadt, Germany), administered
via subcutaneous injection three times weekly at a dose
of either 44 or 22 μg); one pegylated IFN β-1a (Plegridy®
(Biogen, Cambridge, Massachusetts, USA), administered
via subcutaneous injection every 2 weeks at a dose of
125 μg); and two equivalent IFN β-1b (Betaferon® (Bayer,
Leverkusen, Germany) and Extavia® (Novartis, Bale,
Switzerland), both administered via subcutaneous injec-
tion every other day at a dose of 250 μg). Moreover,
there are two licensed formulations of GA (Copaxone®
(Teva, Petah Tikva, Israel)), both administered via sub-
cutaneous injection: one at a dose of 20 mg daily, and
another at a dose of 40 mg three times weekly. The
mechanisms by which either type of drug exerts its
effects in patients with MS are not fully understood, but
it is now thought that these drugs induce a broad immu-
nomodulatory effect that modifies the immune processes
responsible for the pathogenesis of MS.
Though several systematic reviews incorporating net-
work meta-analyses (NMAs) have considered the com-
parative effectiveness of treatments for RRMS, these
have considered doses that do not correspond to the
marketing authorisation and thus are not relevant to
clinical practice (Tramacere et al. [3], Filippini et al. [4]),
excluded relevant doses within drugs’ marketing
authorisations (Tolley et al. [5]), or included trials across
differing severities of MS (Hadjigeorgiou et al. [6]). Our
goal in this systematic review and NMA is to provide an
up-to-date and consistent summary of the comparative
effectiveness of IFN-β and GA on annualised relapse rate
(ARR), disability progression and discontinuation due to
adverse events (AEs) in RRMS, using evidence from
within the drugs’ recommended dosages.
Methods
This systematic review was part of a larger evidence syn-
thesis project considering the effectiveness of treatments
for several types of MS. Our protocol is registered on
PROSPERO as CRD42016043278. The methods and
results described here draw on our closely related work
for the UK National Institute for Health and Care Excel-
lence, the full report of which was provided to the
National Institute for Health Research [2]. In the original
protocol, we described that we would stratify compari-
sons by type of MS. Here, we report clinical effectiveness
findings relating to RRMS specifically.
Searches
We identified and examined past relevant systematic
reviews, conducted update searches in multiple data-
bases, checked references of included studies, contacted
experts in the field, and screened websites for relevant
publications. We undertook the main database searches
in January and February 2016. These update searches
were limited by date to the beginning of 2012 (the year
the searches were undertaken for the last comprehensive
systematic review and NMA by Filippini et al. [4])
onwards, although we included trials without regard to
publication date. This review was chosen because of the
breadth of its scope, search strategy and eligibility
criteria. A full record of searches is provided in
Additional file 1.
We included: a) randomised controlled trials published
as full-text reports in English (as well as systematic
reviews, or meta-analyses to enable reference checking),
b) in people diagnosed with RRMS, c) where the inter-
vention was one of the drugs used within indication at
the recommended dosage according to the summary of
product characteristics as authorised by the European
Medicines Agency (EMA), and d) where the comparator
was placebo or best supportive care without DMTs, or
another of the interventions when used within indica-
tion. Included trials had patient populations primarily
comprised of RRMS patients. Our primary outcomes
were relapse frequency, disease progression, and discon-
tinuation due to adverse events. Outcomes assessed were
relapse rate, time to progression, or discontinuation due
to adverse events as outcomes. Full exclusion criteria
can be found in the review protocol.
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Study selection
First, two authors (XA and GJMT) independently exam-
ined relevant past systematic reviews (including Trama-
cere et al. [3], Filippini et al. [4], and Clerico et al. [7])
for studies meeting the inclusion criteria. We verified in-
clusion of these studies by examining their full text. For
updated and new searches, we collected all retrieved re-
cords in a specialised database and removed duplicate
records. We pilot-tested a screening form based on the
predefined study inclusion and exclusion criteria. Subse-
quently, two reviewers (XA and GJMT) applied the in-
clusion/exclusion criteria and screened all identified
bibliographic records on title/abstract and then using
full texts. Any disagreements over eligibility were re-
solved through consensus or by a third party reviewer
(AC). Reasons for exclusion of full text papers were
documented.
Appraisal and extraction
All primary studies were appraised using the Cochrane
risk of bias assessment tool [8]. For all included studies,
the relevant data were extracted independently by two
reviewers using a data extraction form informed by the
Centre for Reviews and Dissemination [9]. Extracted data
were entered into summary evidence Tables. A sample
data extraction form is available in Additional file 1. Un-
certainty and/or any disagreements were cross-checked
with recourse to a third reviewer where necessary and
resolved by discussion.
Meta-analysis
We undertook separate meta-analyses corresponding to
each of our review outcomes. Data preparation methods
to generate summary effect sizes for each study are de-
tailed in Additional file 1.
First, for relapse frequency, we elected to meta-analyse
rate ratios (RR) of relapses as an overall measure. This
was the most commonly reported measure for relapse
frequency. Where necessary, we converted arm-level
data into rate ratios. Where studies presented different
estimates for relapse frequency, we preferred estimates
of protocol-defined, clinician-confirmed relapses over
non-protocol-defined relapses or self-reported relapses.
Second, disease progression is frequently defined in
clinical trials of DMTs in MS using the Expanded
Disability Status Scale (EDSS), a scale which ranges from
0 to 10. While the EDSS is described as a disability scale
(and thus, trials present this as disability progression), it
is perhaps better understood as a scale measuring im-
pairment and mobility. We used hazard ratios (HR) to
examine differences between study arms in time to
progression, where progression was confirmed at either
3 or 6 months after an initial signal (generally an
increase in EDSS of 0.5 or 1.0 points). We separated
estimates for progression confirmed at 3 months and
confirmed at 6 months, as we could not establish
whether measures were commensurate.
Third, we estimated models for discontinuation due to
AEs, using risk ratios as a summary measure. We also
estimated one model with studies closest to 24 months
of follow-up. This was because risk ratios are time
dependent and we could not reliably estimate
person-years of follow-up in each arm across all studies
to convert study-level estimates to rate ratios.
We pooled outcomes for each intervention-comparator
contrast using random effects meta-analysis in Stata v14
and examined these pairwise meta-analyses for heterogen-
eity, measured as Cochran’s Q and I2. Subsequently, we
used the package -network- [10] in Stata v14 to estimate
network meta-analyses. We used a common heterogeneity
model, where the between-studies variance is assumed
equal across comparisons. After estimating a consistency
model (i.e. where direct evidence for a contrast between
two treatments is assumed to agree with indirect evidence
for that contrast), we checked for inconsistency using an
omnibus Wald test from a design-by-treatment inter-
action model and the side-splitting method to test for dif-
ferences in the effectiveness estimates between direct and
indirect evidence. Where evidence of inconsistency
existed, we considered the direction of inconsistency. We
also assessed transitivity conceptually by examining
networks of evidence for imbalance of trial-level effect
modifiers (e.g. sex, age and duration of MS diagnosis; date
of trial publication), though we did not have enough
studies on each comparison to undertake network
meta-regression.
Lastly, we used a bootstrapping method to resample
from our estimates of intervention effectiveness and
develop probabilities of each treatment’s relative position
to the others. We then used the surface under the
cumulative ranking curve (SUCRA) to produce a unified
ranking of treatments.
Publication bias
We aimed to use funnel plots to examine studies for the
presence of asymmetry, possibly due to publication bias,
other reporting biases, heterogeneity or methodological
inadequacies in included studies, in pairwise compari-
sons where there were more than 10 studies for an
intervention-comparator contrast.
Results
Search results
We identified 6420 potentially relevant records. We
removed 6146 records which did not meet our inclusion
criteria at title/abstract stage, leaving 274 records to be
examined at full-text. Among these, we excluded 232,
leading to 42 publications meeting our inclusion criteria
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and corresponding to 24 primary studies. Study selection
is summarised in Fig. 1. Additional studies related to
other MS phenotypes and are described in the full report
of our work for the National Institute for Health and
Care Excellence [2].
Excluded studies
We excluded two trials in relevant populations and in-
terventions because they did not present relevant out-
comes (Schwartz 1997 [11]) or did not present outcomes
in a form suitable for meta-analysis (Mokhber 2014
[12]). We also excluded one small trial with a mixed
RRMS/SPMS population (REMAIN 2012 [13], RRMS
n = 13) as treatment switching was explicitly allowed
and data were not stratified by type of MS. Break-
down of studies by exclusion criterion is summarised
in Additional file 2.
Included studies
We included 24 trials published between 1987 and 2015.
Included studies are detailed in Table 1. In total, 14 trials
were placebo-controlled, of which three (BRAVO 2014
[14], CONFIRM 2012 [15] and Kappos 2011 [16]) prin-
cipally aimed to test the effectiveness of a new agent
against either IFN-β or GA alongside a placebo control.
The remaining 10 trials only compared active drugs
against each other. One trial (AVANTAGE 2014 [17])
reported only adverse events data. The modal follow-up
was 24 months.
Risk of bias
Risk of bias assessments are detailed in Table 2. All stud-
ies that adequately detailed their method of randomisa-
tion (n = 15, 63%) were appraised as being at low risk of
bias in this domain. A similar number of studies (n = 15)
were judged to be at low risk of bias from allocation
concealment, though one study (Bornstein 1987 [18])
was classed as at high risk of bias in this domain. We
judged that most studies were at high risk of bias in blind-
ing of participants and personnel (n = 24, 83%) and blinding
of outcome assessment (n = 18, 75%) due to a combination
of injection site reactions in placebo-controlled trials and
an open label design. Five studies (21%) were at high risk of
bias from incomplete outcome data due to differential
attrition between arms, and we believed that four studies
(17%) were at high risk of bias from selective reporting. Fi-
nally, most studies (n = 17, 71%) were at high risk of bias
from other sources, generally stemming from industry
sponsorship.
Annualised relapse rates
Direct evidence from comparisons is shown in Fig. 2. All
drugs had a beneficial effect on ARR as compared to
placebo. None of the pooled comparisons showed
evidence of a statistically significant effect favouring one
drug over another drug. Heterogeneity quantified by I2
ranged from 0% (IFN β-1b 250 μg SC every other day,
IFN β-1a 30 μg IM once a week) to 43% (IFN β-1a 44 μg
SC thrice weekly) and 73% (GA 20 mg SC once daily).
However, there were too few studies in each comparison
to enable exploration of heterogeneity.
Findings derived from the NMA for comparisons
between each drug and placebo substantially mirrored
those of the pairwise comparisons, and reflected statisti-
cally significant reductions in ARR in patients receiving
active drugs (see Table 3). There was little evidence of
superiority of one drug over another. However, GA
20 mg SC once daily (RR = 0.82, 95% CI [0.73, 0.93]),
Total from 
database searches
n=14,445
Total from 
key reviews
n=90
Total from 
other sources
n=31
Records screened after duplicates and 
records indexed as conference abstracts 
or observational studies removed
n=6,420
Full-text articles screened for eligibility
n=274
Primary studies in meta-analysis
n=42 (24 trials)
Records excluded on title 
and abstract
n=6,146
Full-text articles excluded
n=232
Fig. 1 PRISMA flowchart
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Table 1 Characteristics of included studies
Study ID
MS type (diagnostic criteria)
Study details Characteristics of participants at
baseline
Intervention Participants
ADVANCE 2014
RRMS (2005 McDonald criteria)
Country: USA, Belgium, Bulgaria,
Canada, Chile, Colombia, Croatia,
Czech Republic, Estonia, France,
Georgia, Germany, Greece, India,
Latvia, Mexico, Netherlands, New
Zealand, Peru, Poland, Romania,
Russian Federation, Serbia, Spain,
Ukraine, United Kingdom.
No. of countries: 26
Centres: 183
Study period: June 2009
and November 2011.
Sponsor: Biogen Idec
Mean age: 36.5 (9.9)
Mean sex: 71% female
Race: 82% white
EDSS Score: 2.5
Relapse rate: 1.6 within the
previous 12 months, 2.6
within the previous 36 months
Time from diagnosis of MS: 3.6 years
Other clinical features of MS: Time
from first MS symptoms: 6.6 years
Arm 1: pegylated IFN
β-1a 125 μg SC every
2 weeks (Plegridy)
Arm 2: Placebo
Randomised
512 arm 1
500 arm 2
AVANTAGE 2014
RRMS/CIS, diagnostic criteria
unclear
Country: France
No. of countries: 1
Centres: 61
Study period: March 2006–April
2008, 3 months follow up
Sponsor: Bayer
Mean age: 38.7
Mean sex: 75% female
Race: NA
EDSS Score: 1.8 ± 1.3
Mean number of relapse
rate: 2.1 ± 1.1
Time from diagnosis of
MS: 3.3 (6.4) years
Other clinical features
of MS: NA
Arm 1: IFN β-1b
250 μg SC every other
day (Betaferon) via
Betaject
Arm 2: IFN β-1b
250 μg SC every other
day (Betaferon) via
Betaject light
Arm 3: IFN β-1a 44 SC
three times weekly
(Rebif) via Rebiject II
Included:
73 arm 1
79 arm 2
68 arm 3
BECOME 2009
RRMS/CIS (likely McDonald
2001 or 2005)
Country: USA
No. of countries: 1
Centres: 2
Study period: Not specified,
follow up over 2 years
Sponsor: Bayer Schering pharma
Mean age: 36
Mean sex: 69% females
Race: 52% white
Median EDSS Score: 2
Relapse rate: 1.8 and 1.9 ARR
Time from diagnosis of
MS: between 0.9 and 1.2
Other clinical features of MS: 81%
RRMS, 19% CIS; MSFC median 0.13
Arm 1: IFN β-1b
250 μg SC every
other day (Betaferon)
Arm 2: GA 20 mg
SC daily (Copaxone)
Randomised
36 arm 1
39 arm 2
BEYOND 2009
RRMS (McDonald 2005)
Country: Not specified
No. of countries: 26
Centres: 198
Study period: November, 2003,
and June, 2005. Follow up
between 2 and 3.5 years
Sponsor: Bayer
Mean age 35.6
Mean sex: 69.4% female
Race: 91.9% white
EDSS Score: 2.33
Relapse rate: 1.6 relapses in last year
Time from diagnosis of MS: 5.2 years
Other clinical features of MS:
3.6 relapses previously; 70.6% had
two or more relapses in past 2 years
Arm 1: IFN β-1b
250 μg SC every
other day (Betaferon)
Arm 2: GA 20 mg
SC daily (Copaxone)
Randomised
897 arm 1
448 arm 2
Bornstein 1987
RRMS (Poser)
Country: USA
No. of countries: 1
Centres: Not specified
Study period: Not specified,
follow up over 2 years
Sponsor: public (grant from the
National Institute of Neurological
and Communicative Disorders
and Stroke and grant from the
National Institutes of Health)
Mean age: 30.5
Mean sex: 42% male/58% female
Race: 96% white
EDSS Score: 3.11
Relapse rate: 3.85 over 2 years
Time from diagnosis of MS: 5.5 years
duration of disease
Other clinical features of MS: NA
Arm 1: GA 20 mg
SC daily (Copaxone)
Arm 2: Placebo
Randomised
25 arm 1
25 arm 2
BRAVO 2014
RRMS (McDonald 2005)
Country: US, Bulgaria, Croatia,
Czech Republic, Estonia, Georgia,
Germany, Israel, Italy, Lithuania,
Macedonia, Poland, Romania,
Russia, Slovakia, South Africa,
Spain, Ukraine and others not
specified
No. of countries: 18
Centres: 140
Study period: April 2008 to June
2011. 24 months follow up
Sponsor: Teva Pharmaceutical
Mean age: Median: 37.5 placebo,
38.5 IFN
Mean sex: 71.3% females in placebo
arm, 68.7% females in IFN arm
Race: N/A
EDSS Score: Median: 2.5 placebo,
2.5 IFN
Median Relapse rate: previous year:
1.0 placebo, 1.0 IFN;
previous 2 years: 2.0 placebo, 2.0 IFN
Median Time from diagnosis of MS:
1.2 placebo, 1.4 IFN
Arm 1: IFN β-1a
30 μg IM once weekly
(Avonex)
Arm 2: Oral placebo
once-daily with neur-
ologist monitoring
Randomised
447 arm 1
450 arm 2
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Table 1 Characteristics of included studies (Continued)
Study ID
MS type (diagnostic criteria)
Study details Characteristics of participants at
baseline
Intervention Participants
Industries Other clinical features of MS: NA
Calabrese 2012
RRMS (McDonald 2005)
Country: Italy
No. of countries: 1
Centres: 1
Study period: 1 Jan 2007–30
June 2008
Follow up over 2 years
Sponsor: grant from Merck
Serono S.A
Mean age: 36.5 (9.9)
Mean sex: 70.2% of female/20.8% of
male
Race: NA
EDSS Score: 2.1 (1.1)
Relapse rate: 1.2 (0.7)
Time from diagnosis of MS: 5.6 years
(2.4)
Other clinical features of MS: None
Arm 1: IFN β-1a 44
SC three times weekly
(Rebif)
Arm 2: IFN β-1a 30 μg
IM once weekly
(Avonex)
Arm 3: GA 20 mg SC
daily (Copaxone)
Randomised
55 arm 1
55 arm 2
55 arm 3
CombiRx 2013
RRMS (McDonald 2001, Poser)
Country: United States, Canada
No. of countries: 2
Centres: 68
Study period: January 2005–April
2012. Minimally 36 months
follow up
Sponsor: NIH, with materials
provided by Biogen and Teva
Mean age 38.3
Mean sex: 70.3% female
Race: 87.6% white
EDSS Score: 2.0
Relapse rate: 1.7 relapses in last year,
on average
Time from diagnosis of MS: 1.2
Other clinical features of MS:
NA
Arm 1: IFN β-1a 30 μg
IM once weekly
(Avonex)
Arm 2: GA 20 mg
SC daily (Copaxone)
Randomised
250 arm 1
259 arm 2
CONFIRM 2012
RRMS (McDonald 2005)
Country: USA, Belarus, Belgium,
Bosnia and Herzegovina, Bulgaria,
Canada, Costa Rica, Croatia,
Czech Republic, Estonia, France,
Germany, Greece, India, Ireland,
Israel, Latvia, Macedonia, Mexico,
Republic of Moldova, New
Zealand, Poland, Puerto Rico,
Romania, Serbia, Slovakia, Spain,
Ukraine
No. of countries: 28
Centres: 200
Study period: 2 year follow up
Sponsor: Biogen idec
Mean age 36.8
Mean sex: 70% female
Race: 84% white
EDSS Score: 2.6
Relapse rate: 1.4 in prior 12 months
Time from diagnosis of MS: 4.6 years
Other clinical features of MS:
any prior DMTs (%) = 29%
Arm 1: GA 20 mg
SC daily (Copaxone)
Arm 2: 2 placebo
capsules orally thrice
daily
Randomised
360 arm 1
363 arm 2
Cop1 MSSG 1995
RRMS (Poser)
Country: USA
No. of countries: 1
Centres: 11
Study period: October, 1991, and
May, 1992. 2 year follow up.
Sponsor: the FDA orphan drug
program, the National multiple
sclerosis society, and TEVA
pharmaceutical
Mean age 34.4.
Mean sex: 73% female
Race: 94% white
EDSS Score: 2.6
Relapse rate: 2.9 prior 2-year rate
MS duration:6.9 years
Other clinical features of MS:
ambulation index = 1.1
Arm 1: GA 20 mg
SC daily (Copaxone)
Arm 2: Placebo
Randomised
125 arm 1
126 arm 2
ECGASG 2001
RRMS (Poser)
Country: Canada
No. of countries: 7
Centres: 29
Study period: Enrollment started
in February 1997 and concluded
in November 1997. 9 month
follow up
Sponsor: Teva Pharmaceutical
Industries
Mean age 34
Mean sex: NA
Race: NA
EDSS Score: 2.4
Relapse rate: 2.65
Disease duration (years): 8.1
Other clinical features of MS:
ambulation index = 1.15
Arm 1: GA 20 mg
SC daily (Copaxone)
Arm 2: Placebo SC
injections
Randomised
119 arm 1
120 arm 2
Etemadifar 2006
RRMS (Poser)
Country: Iran
No. of countries: 1
Centres: 1
Study period: September 2002
and September 2004. 24 month
follow up
Sponsor: Not specified
Mean age 28.5
Mean sex: 76% female
Race: NA
EDSS Score: 2.0
Relapse rate 1 year prior: 2.2
Time from diagnosis of MS: 3.2 years
Other clinical features of MS: None
Arm 1: IFN β-1b
250 μg SC every other
day (Betaferon)
Arm 2: IFN β-1a 30 μg
IM once weekly
(Avonex)
Arm 3: IFN β-1a 44
SC three times weekly
(Rebif)
Randomised
30 arm 1
30 arm 2
30 arm 3
EVIDENCE 2007
RRMS (Poser)
Country: USA, France, UK,
Norway, Austria, Germany,
France, Finland, Sweden, Canada
Mean age 37.9
Mean sex: 74.8% female
Race: 91.0% Caucasian
Arm 1: IFN β-1a 44
SC three times weekly
(Rebif)
Randomised
339 arm 1
338 arm 2
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Table 1 Characteristics of included studies (Continued)
Study ID
MS type (diagnostic criteria)
Study details Characteristics of participants at
baseline
Intervention Participants
No. of countries: 10
Centres: 56
Study period: Unclear. Minimally
48 weeks follow up, average 64.2
Sponsor: Serono
EDSS Score: 2.3
Median: 2.0
Relapse rate: 2.6 Median 2.0 relapses
in last 2 years
Duration of MS: 6.6. Median:
4.0–4.1 years
Other clinical features of MS:
Time since last relapse (months):
Median 3.9 to 4.4; mean 5.1
Arm 2: IFN β-1a 30 μg
IM once weekly
(Avonex)
GALA 2013
RRMS (McDonald 2005)
Country: United States, Bulgaria,
Croatia, Germany, Poland,
Romania, and Ukraine and others
No. of countries: 17
Centres: 142
Study period: Not specified.
12 months follow up.
Sponsor: TEVA pharmaceutical
industries
Mean age 37.6
Mean sex: 68% female
Race: 98% Caucasian
EDSS Score: 2.7
Relapse rate: 1.3 in the prior
12 months, 1.9 in the prior
24 months
Time from diagnosis of MS: NA
Other clinical features of MS:
Time from onset of first symptoms
of MS = 7.7 years
Arm 1: GA 40 mg
SC three times weekly
(Copaxone)
Arm 2: SC placebo
injections
Randomised
943 arm 1
461 arm 2
GATE 2015
RRMS (McDonald 2010)
Country: USA, Belarus, Bosnia and
Herzegovina, Bulgaria, Croatia,
Czech Republic, Estonia, Georgia,
Germany, Italy, Mexico, Republic
of Moldova, Poland, Romania,
Russian Federation, Serbia, South
Africa, Ukraine, United Kingdom
No. of countries: 20
Centres: 118
Study period: Recruited between
December 7, 2011, and March 21,
2013; last follow-up December 2,
2013. Follow up 9 months
(double-blind follow-up) + add-
itional 15 months (open-label)
Sponsor: Synthon BV
Mean age 33.1
Mean sex: 66.4% female
Race: NA
EDSS Score: 2.7
Relapse rate: 1.9 in prior 2 years
Time from diagnosis of MS: NA
Other clinical features of MS:
• Time to onset of first symptoms
to randomisation (years): 5.9
• No history of prior disease
treatment: 16.1%
Arm 1: GA 20 mg SC
daily (Copaxone)
Arm 2: Placebo
Randomised
357 arm 1
84 arm 2
IFNB MSSG 1995
RRMS (Poser)
Country: USA and Canada
No. of countries: 2
Centres: 11
Study period: after 2 years of
follow-up, all subjects were given
the option of continuing treat-
ment in a double-blind fashion,
extending the total treatment
period to 5.5 years for some
patients
Sponsor: Triton Biosciences,
Berlex Laboratories
Mean age 35.6
Mean sex: 70% female
Race: 94% white
EDSS Score: 2.9
Relapse rate: 3.5 in prior 2 years
Time from diagnosis of MS:4.3 years
Other clinical features of MS:
Baseline Scripps neurological rating
scale: 80.8
Arm 1: IFN β-1b
250 μg SC every other
day (Betaferon)
Arm 2: SC injections
placebo
Randomised
124 arm 1
123 arm 2
IMPROVE 2012
RRMS (McDonald 2005)
Country: Italy, Germany, Serbia,
Canada, Bulgaria, Estonia,
Lithuania, Romania, Russia, Spain
No. of countries: 10
Centres: 5
Study period: December 2006 to
February 2009.
Follow up 16 weeks for the
double-blind phase, then
24 weeks where all patients re-
ceived interferon beta 1-a, at last
4 weeks of safety period
observation
Sponsor: Merck Serono S.A.
Mean age NA
Mean sex: NA
Race: NA
EDSS Score: NA
Relapse rate: NA
Time from diagnosis of MS: NA
Other clinical features of MS: NA
Arm 1: IFN β-1a 44 SC
three times weekly
(Rebif)
Arm 2: SC injections
of placebo
Randomised
120 arm 1
60 arm 2
INCOMIN 2002
RRMS (Poser)
Country: Italy
No. of countries: 1
Mean age 36.9
Mean sex: 65% female
Arm 1: IFN β-1b
250 μg SC every other
Randomised
92 arm 1
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Table 1 Characteristics of included studies (Continued)
Study ID
MS type (diagnostic criteria)
Study details Characteristics of participants at
baseline
Intervention Participants
Centres: 15
Study period: October, 1997, and
June, 1999. 2 year follow up
Sponsor: Istituto Superiore di
Sanita’ of the Italian Ministry of
Health and the Italian MS Society
Race: NA
EDSS Score: 1.97
Relapse rate 2 years prior: 1.45
Time from diagnosis of MS: 6.3 years
Other clinical features of MS: None
day (Betaferon)
Arm 2: IFN β-1a 30 μg
IM once weekly
(Avonex)
96 arm 2
Kappos 2011
RRMS (McDonald 2001)
Country: Belgium, Bulgaria,
Canada, Czech Republic,
Denmark, France, Germany, Italy,
Mexico, Romania, Russian
Federation, Serbia, Slovakia,
Spain, Switzerland, Ukraine,
United Kingdom, USA and others
No. of countries: 20
Centres: 79
Study period: Not specified. Up
to 96 weeks follow up.
Sponsor: F Hoffmann-La Roche
Ltd., Biogen Idec Inc
Mean age 37.5
Mean sex: 65% female
Race: 96% white
EDSS Score: 3.3
Relapse rate: NA
Time from diagnosis of MS: median
only
Other clinical features of MS: NA
Arm 1: IFN β-1a 30 μg
IM once weekly
(Avonex)
Arm 2: placebo
injection every other
week
Randomised
55 arm 1
54 arm 2
Knobler 1993
RRMS (Poser)
Country: USA
No. of countries: 1
Centres: 3
Study period: June and October
1986. Follow up 3 years
(24 weeks of initial follow-up for
the 5 groups then all the patients
that had received 0.8 mU, 4MU
and 16MU for 24 weeks received
a dose of 8MU from week 24 to
3 years)
Sponsor: Triton Biosciences, Inc.
and Berlex Laboratories, Inc
Mean age 35.6
Mean sex: 48% female
Race: NA
EDSS Score: 3.1
Mean exacerbation in prior
2 years: 2.84
Time from diagnosis of MS: 6.6 years
Other clinical features of MS:
mean Scripps Neurological Rating
Scale (NRS): 76.6
Arm 1: IFN β-1b
250 μg SC every other
day (Betaferon)
Arm 2: Subcutaneous
injection of placebo
(1 mL like Betaseron 8
MU)
Randomised
6 arm 1
7 arm 2
MSCRG 1996
RRMS (Poser)
Country: USA
No. of countries: 1
Centres: 4
Study period: November, 1990
to early 1993
2 years follow up for all-patients
+ 2 additional years for patients
completing dosing before the
end of the first period of
follow-up.
Sponsor: National Institutes of
Health, National Institute of
Neurological Disorders and
Stroke (NINDS) grant R01–26321
and Biogen, Inc.
Mean age 36.8
Mean sex: 73.7% female
Race: 93% white
EDSS Score: 2.4
Relapse rate: 1.2
MS duration (years): 6.5
Other clinical features of MS: None
Arm 1: IFN β-1a 30 μg
IM once weekly
(Avonex)
Arm 2: Placebo
Randomised
158 arm 1
143 arm 2
PRISMS 1998
RRMS (Poser)
Country: Australia, Belgium,
Canada, Finland, Germany,
Netherlands, Sweden,
Switzerland, UK
No. of countries: 9
Centres: 22
Study period: May 1994 to
February 1995 with 2 years
follow up.
Sponsor: Ares- Serono
Mean age Median: 34.9
Mean sex: 69% female
Race: NA
EDSS Score: 2.5 (SD 1.2)
Relapse rate: 3.0 (SD 1.2)
Time from diagnosis of MS: Median:
5.3 years)
Other clinical features of MS: NA
Arm 1: IFN β-1a 22 μg
SC three times weekly
(Rebif)
Arm 2: IFN β-1a 44 SC
three times weekly
(Rebif)
Arm 3: Placebo
Randomised
189 arm 1
184 arm 2
187 arm 3
REFORMS 2012
RRMS (McDonald 2005, Poser)
Country: USA
No. of countries: 1
Centres: 27
Study period: December
2006–November 2007.
12 weeks follow up
Sponsor: EMD Serono, Pfizer
Mean age 40.52 (SD 9.65)
Mean sex: 70% female
Race: 87.6% white
EDSS Score: NA
Relapse rate: 1.33 (SD 0.49) (of those
with relapses)
Time from diagnosis of MS: 1.47 yrs.
Arm 1: IFN β-1a 44 SC
three times weekly
(Rebif)
Arm 2: IFN β-1b
250 μg SC every other
day (Betaferon)
Randomised
65 arm 1
64 arm 2
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IFN β-1a 44 μg SC thrice weekly (0.85, [0.76, 0.95]) and
IFN β-1b 250 μg SC every other day (0.86, [0.76, 0.97])
all produced significant reductions in ARR as compared
to IFN β-1a 30 μg IM once a week. Ranking of the drugs
suggested that the drug with the highest cumulative
probability of superiority was GA 20 mg SC once daily.
We found no evidence of inconsistency.
Sensitivity analyses
Several characteristics of the trials included in this network
suggested that additional analyses would confirm the
robustness of our findings. All of these analyses were post
hoc. First, after exclusion of the REFORMS 2012 [19] trial
from the analysis (where relapses were self-reported by sub-
jects instead of being documented by an examining neur-
ologist), effect estimates remained essentially unchanged
for all pairwise comparisons. Second, we compared findings
for studies with ‘true’, blinded placebos against studies that
did not have blinded placebos. That is, several studies did
not deliver placebos via the same route of administration
[14–16]. We found that effects for these drugs against pla-
cebo were robust to inclusion of a covariate in the model
for trials without a blinded placebo. Third, after exclusion
of the Bornstein 1987 [18] trial that was an outlier in the
comparison between GA 20 mg SC once daily and placebo,
the pooled rate ratio for relapses still suggested a reduction
in ARR as compared to placebo (RR = 0.71, 95% CI [0.62,
0.82]), with I2 of 0% (see Additional file 2). Re-estimation of
the NMA yielded a change in the SUCRA-based rankings,
with GA 20 mg SC once daily now ranked third, but point
estimates and confidence intervals were not substantially
different in the new model.
Time to progression confirmed at three months
Direct evidence from comparisons is shown in Fig. 3. GA
40 mg thrice weekly was not represented in this analysis.
Comparison of drugs against placebo showed a mixed pat-
tern of results. None of the three direct comparisons
between active drugs suggested a benefit of one over an-
other. Most comparisons were informed by only one study.
Comparisons for active drugs vs. placebo were similar
between the NMA and the pairwise meta-analyses (see
Table 4). Notably, additional information from indirect
comparisons yielded a more precise estimate of effective-
ness for both IFN β-1a 30 μg IM once a week vs placebo
(HR = 0.73, 95% CI [0.53, 1.00], p = 0.0499) and GA
20 mg SC once daily (0.76, [0.60, 0.97]). Comparisons
between active drugs estimated from the NMA did not
indicate that any one drug was statistically better than
the others, but ranking of the drugs suggested that the
drug with the highest cumulative probability of superior-
ity was IFN β-1a 44 μg SC thrice weekly. We found no
evidence of inconsistency.
Time to progression confirmed at six months
Direct evidence from comparisons is shown in Fig. 3. All
comparisons drew from a single study, except for IFN
β-1a 30 μg IM once a week as compared to placebo.
Table 1 Characteristics of included studies (Continued)
Study ID
MS type (diagnostic criteria)
Study details Characteristics of participants at
baseline
Intervention Participants
(3.31)
Other clinical features of MS:
Percentage with no relapse in last
12 months: 24 (18.6%)
Time since onset: 5.12 yrs. (6.68)
Percentage diagnosed with Poser
criteria: 36 (27.9%)
Time since last relapse, of those with
last-year relapses: 3.76 mos (2.93)
Steroid treatment episodes: 0.50
(0.55)
Percentage needing more than one
course of steroids: 49 (38.0%)
REGARD 2008
RRMS (McDonald 2001)
Country: Argentina, Austria, Brazil,
Canada, France, Germany, Ireland,
Italy, Netherlands, Russia, Spain,
Switzerland, UK, and USA
No. of countries: 14
Centres: 80
Study period: February and
December 2004, with 96 weeks
follow up
Sponsor: EMD Serono, Pfizer
Mean age 36.8
Mean sex: 29.5% male
Race: 93.6% white
EDSS Score: 2.34
Relapse rate: Presented as
distribution of relapses; months since
last relapse about 5 on average
Time from diagnosis of MS: Years
since first relapse: 6.2
Other clinical features of MS:
Receiving steroid treatment in last
6 months: 43.7%
Arm 1: IFN β-1a 44 SC
three times weekly
(Rebif)
Arm 2: GA 20 mg SC
daily (Copaxone)
Randomised
386 arm 1
378 arm 2
RRMS relapsing remitting MS, SPMS secondary progressive MS, CIS clinically isolated syndrome, IFN interferon, GA glatiramer acetate, IM intramuscular, SC
subcutaneous, NA not available, EDSS Expanded Disability Status Score
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Only three drugs, GA 20 mg SC one daily, IFN β-1a
30 μg SC once weekly and IFN β-1a pegylated 125 μg
every 2 weeks, were compared against placebo.
In the NMA, estimates for GA 20 mg SC once daily
(HR = 0.82, 95% CI [0.53, 1.26]), IFN β-1a 30 μg IM once
a week (0.68, [0.49, 0.94]) and IFN β-1a pegylated
125 μg every 2 weeks (0.46, [0.26, 0.81]) compared to
placebo mirrored the direct evidence (see Table 4). Indir-
ect comparisons suggested that both IFN β-1a 44 μg SC
thrice weekly (0.47, [0.24, 0.93]) and IFN β-1b 250 μg
Table 2 Risk of bias judgments for included studies
Reference Random sequence
generation
Allocation
concealment
Blinding of participants
and personnel
Blinding of outcome
assessment
Incomplete
outcome data
Selective
reporting
Other sources
of bias
ADVANCE
2014
Low risk Low risk High risk High risk High risk Low risk High risk
AVANTAGE
2014
Unclear risk Unclear risk High risk High risk Unclear risk Low risk Low risk
BECOME
2009
Unclear risk Unclear risk High risk High risk Low risk Low risk High risk
BEYOND
2009
Low risk Low risk High risk High risk Unclear risk Low risk High risk
Bornstein
1987
Unclear risk High risk High risk High risk Low risk Low risk Low risk
BRAVO
2014
Low risk Low risk High risk Low risk Low risk High risk High risk
Calabrese
2012
Low risk Low risk High risk High risk Low risk High risk Low risk
CombiRx
2013
Low risk Low risk Low risk Low risk High risk Low risk Low risk
CONFIRM
2012
Low risk Low risk High risk High risk High risk Low risk High risk
Cop1 MSSG
1995
Unclear risk Low risk High risk High risk Low risk Low risk Low risk
ECGASG
2001
Low risk Low risk High risk High risk Low risk Unclear risk High risk
Etemadifar
2006
Unclear risk Unclear risk High risk High risk Low risk Unclear risk Unclear risk
EVIDENCE
2007
Low risk Low risk High risk High risk Low risk Low risk High risk
GALA 2013 Unclear risk Low risk High risk High risk Unclear risk Low risk High risk
GATE 2015 Low risk Low risk High risk High risk Low risk Low risk High risk
IFNB MSSG
1995
Unclear risk Unclear risk High risk High risk High risk Low risk High risk
IMPROVE
2012
Unclear risk Low risk Unclear risk Unclear risk Unclear risk High risk High risk
INCOMIN
2002
Low risk Low risk High risk High risk Low risk Low risk Low risk
Kappos
2011
Low risk Low risk High risk High risk Low risk High risk High risk
Knobler
1993
Unclear risk Unclear risk High risk High risk Unclear risk Unclear risk High risk
MSCRG
1996
Low risk Unclear risk Low risk Low risk High risk Unclear risk High risk
PRISMS
1998
Low risk Low risk Unclear risk Low risk Low risk Low risk High risk
REFORMS
2012
Low risk Unclear risk High risk High risk Unclear risk Low risk High risk
REGARD
2008
Low risk Unclear risk High risk Low risk Low risk Low risk High risk
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SC every other day (0.34, [0.18, 0.63]) showed evidence
of delaying disability progression as compared to
placebo. The NMA suggested that IFN β-1b 250 μg SC
every other day was superior both to IFN β-1a 30 μg IM
once a week (HR = 0.50, 95% CI [0.29, 0.87]) and to GA
20 mg SC once daily (0.41, [0.21, 0.83]), but these find-
ings were driven by the INCOMIN 2002 trial [20] and
relied on a hazard ratio estimated from summary statis-
tics. Ranking of the drugs suggested that the drug with
the highest cumulative probability of superiority was
IFN β-1b 250 μg SC every other day. Tests of inconsist-
ency in the network did not suggest that direct and
indirect evidence were in disagreement; however, the
network was sparse and only one comparison included
more than one study.
Discontinuation due to AEs
Two NMA models were estimated: one for studies with
24-month follow-up and one including all studies with
the follow-up of greatest maturity. Neither NMA found
evidence that one drug was more likely to lead to dis-
continuation than another. However, confidence inter-
vals were wide and NMA-based estimates were often
numerically different to estimates from the direct
NOTE: Weights are from random effects analysis
.
.
.
.
.
.
.
.
.
.
.
.
.
.
GA 20 mg SC daily vs. Placebo
Bornstein 1987
ECGASG 2001
Cop1 MSSG 1995
CONFIRM 2012
GATE 2015
Subtotal  (I−squared = 72.9%, p = 0.005)
GA 40 mg SC thrice weekly vs. Placebo
GALA 2013
Subtotal  (I−squared = .%, p = .)
IFN β−1a 30 μg IM weekly vs. Placebo
Kappos 2011
BRAVO 2014
MSCRG 1996
Subtotal  (I−squared = 0.0%, p = 0.479)
IFN β−1a 44 μg SC thrice weekly vs. Placebo
IMPROVE 2012
PRISMS 1998
Subtotal  (I−squared = 42.6%, p = 0.187)
IFN β−1a 22 μg SC thrice weekly vs. Placebo
PRISMS 1998
Subtotal  (I−squared = .%, p = .)
IFN β−1a pegylated 125 μg SC every 2 weeks vs. Placebo
ADVANCE 2014
Subtotal  (I−squared = .%, p = .)
IFN β−1b 250 μg SC every other day vs. Placebo
IFNB MSSG 1995
Knobler 1993
Subtotal  (I−squared = 0.0%, p = 0.681)
IFN β−1a 30 μg IM weekly vs. IFN β−1b 250 μg SC every other day
Etemadifar 2006
INCOMIN 2002
Subtotal  (I−squared = 76.4%, p = 0.040)
IFN β−1a 30 μg IM weekly vs. GA 20 mg SC daily
Calabrese 2012
CombiRx 2013
Subtotal  (I−squared = 58.3%, p = 0.121)
IFN β−1a 44 μg SC thrice weekly vs. GA 20 mg SC daily
Calabrese 2012
REGARD 2008
Subtotal  (I−squared = 0.0%, p = 0.339)
IFN β−1a 44 μg SC thrice weekly vs. IFN β−1a 30 μg IM weekly
Calabrese 2012
EVIDENCE 2007
Etemadifar 2006
Subtotal  (I−squared = 31.8%, p = 0.231)
IFN β−1a 44 μg SC thrice weekly vs. IFN β−1a 22 μg SC thrice weekly
PRISMS 1998
Subtotal  (I−squared = .%, p = .)
IFN β−1a 44 μg SC thrice weekly vs. IFN β−1b 250 μg SC every other day
Etemadifar 2006
REFORMS 2012
Subtotal  (I−squared = 0.0%, p = 0.533)
IFN β−1b 250 μg SC every other day vs. GA 20 mg SC daily
BEYOND 2009
BECOME 2009
Subtotal  (I−squared = 0.0%, p = 0.842)
ID
Study
0.25 (0.14, 0.43)
0.67 (0.49, 0.92)
0.70 (0.57, 0.86)
0.71 (0.55, 0.93)
1.05 (0.52, 2.12)
0.62 (0.46, 0.84)
0.66 (0.54, 0.80)
0.66 (0.54, 0.80)
0.56 (0.30, 1.05)
0.74 (0.60, 0.92)
0.82 (0.67, 0.99)
0.77 (0.67, 0.88)
0.43 (0.23, 0.81)
0.67 (0.56, 0.80)
0.60 (0.41, 0.87)
0.73 (0.61, 0.87)
0.73 (0.61, 0.87)
0.64 (0.50, 0.83)
0.64 (0.50, 0.83)
0.70 (0.60, 0.81)
0.78 (0.47, 1.29)
0.70 (0.61, 0.81)
0.88 (0.61, 1.25)
1.40 (1.07, 1.83)
1.12 (0.71, 1.78)
1.00 (0.67, 1.50)
1.49 (1.10, 2.03)
1.25 (0.85, 1.84)
0.80 (0.52, 1.23)
1.03 (0.76, 1.40)
0.95 (0.74, 1.22)
0.80 (0.52, 1.23)
0.83 (0.70, 0.99)
1.16 (0.81, 1.65)
0.90 (0.73, 1.10)
0.95 (0.80, 1.13)
0.95 (0.80, 1.13)
1.02 (0.72, 1.43)
1.41 (0.54, 3.70)
1.05 (0.76, 1.45)
1.06 (0.92, 1.22)
1.12 (0.65, 1.93)
1.06 (0.93, 1.22)
ratio (95% CI)
Rate
14.91
22.75
26.54
24.48
11.32
100.00
100.00
100.00
5.02
42.61
52.36
100.00
25.22
74.78
100.00
100.00
100.00
100.00
100.00
92.13
7.87
100.00
46.76
53.24
100.00
44.53
55.47
100.00
33.65
66.35
100.00
18.24
57.03
24.73
100.00
100.00
100.00
88.83
11.17
100.00
93.87
6.13
100.00
Weight
%
Favours treatment 1  Favours treatment 2 
1.25 .5 2
Fig. 2 Pairwise meta-analyses for annualised relapse rate. IFN: interferon, GA: glatiramer acetate, IM: intramuscular, SC: subcutaneous
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evidence alone. Moreover, both networks of evidence
included some indication of inconsistency. In the
24-month follow-up model, the sidesplitting test sug-
gested that direct and indirect evidence were in con-
flict for the comparison between GA 20 mg SC once
daily and placebo, with indirect evidence suggesting
that risk of discontinuation due to AEs was higher
than presented in the direct evidence (p = 0.037). In
the all-studies model, the overall Wald test suggested
some signal of inconsistency (p = 0.09), though side-
splitting tests did not indicate an obvious source of
inconsistency. Full results are in Additional file 2.
Discussion
Meta-analyses confirmed that the different formula-
tions of IFN-β and GA reduce ARR and generally
delay progression as defined in these trials. There
was little evidence that any one drug was superior to
others, except for progression confirmed at 6 months,
but networks were especially sparse. Findings for
discontinuations due to AEs, which are intended to
be indicative, did not suggest that one drug was
more likely to result in discontinuation than another,
but these findings relied on networks with some lim-
ited evidence of inconsistency.
Challenges with the clinical evidence
These conclusions are tempered by several consider-
ations. Analyses did not show a clear ‘winner’ across
outcomes, and, again, comparisons between drugs esti-
mated as part of NMA models were in the main incon-
clusive. Though the main model for ARR was relatively
well populated, analyses for time to progression con-
firmed at six months were especially sparse. In particu-
lar, several comparisons of drugs vs. placebo estimated
as part of this last model relied exclusively on indirect
evidence. Moreover, analyses for time to progression
confirmed at three and at six months did not show a
consistent pattern, except that all drugs were beneficial
in delaying progression where progression was defined
using the EDSS. This is particularly concerning, as
progression confirmed at six months is considered to be
a ‘stronger’ outcome than progression confirmed at three
months.
Measurement of disease progression also relied on the
EDSS, a measure that, while broadly accepted in clinical
trials, may be of dubious value in measuring disability
per se. The EDSS is heavily weighted towards mobility
over other important aspects of disability affected by
disease progression in MS, such as cognitive function.
Additionally, progression outcomes based on confirmed
Table 3 Network meta-analysis results for annualised relapse ratea
Drug SUCRA GA
20 mg
daily
PegIFN β-1a
125 μg every
2 weeks
GA 40 mg
thrice weekly
IFN β-1a 44 μg
SC thrice
weekly
IFN β-1b 250 μg
SC every other
day
IFN β-1a 22 μg
SC thrice
weekly
IFN β-1a
30 μg IM
weekly
Placebo
GA 20 mg daily 0.77 1.01 (0.77, 1.33) 1.00 (0.80, 1.24) 0.97 (0.85, 1.10) 0.95 (0.86, 1.05) 0.91 (0.76, 1.08) 0.82 (0.73,
0.92)
0.65
(0.59,
0.72)
PegIFN β-1a
125 μg every
2 weeks
0.73 0.98 (0.71, 1.35) 0.95 (0.72, 1.26) 0.94 (0.71, 1.23) 0.89 (0.66, 1.21) 0.81 (0.62,
1.06)
0.64
(0.50,
0.83)
GA 40 mg thrice
weekly
0.70 0.97 (0.77, 1.22) 0.96 (0.77, 1.19) 0.91 (0.71, 1.17) 0.82 (0.66,
1.03)
0.66
(0.54,
0.80)
IFN β-1a 44 μg
SC thrice weekly
0.64 0.99 (0.86, 1.13) 0.94 (0.80, 1.10) 0.85 (0.76,
0.95)
0.68
(0.60,
0.76)
IFN β-1b 250 μg
SC every other
day
0.56 0.95 (0.79, 1.14) 0.86 (0.76,
0.97)
0.69
(0.62,
0.76)
IFN β-1a 22 μg
SC thrice weekly
0.43 0.91 (0.76,
1.08)
0.72
(0.61,
0.85)
IFN β-1a 30 μg
IM weekly
0.18 0.80
(0.72,
0.88)
Placebo 0
Test for inconsistency (χ2,
df, p)
11.71,
11, 0.38
aFindings are expressed as rate ratio (RR) with 95% CI
IFN interferon, GA glatiramer acetate, IM intramuscular, SC subcutaneous, SUCRA surface under the cumulative ranking curve
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progression at 3 or 6 months overestimate the accumu-
lation of permanent disability by up to 30% [21]. This is
in part because recovery from relapses may take longer
than several months, and thus ‘confirmed’ progression
may reflect residual relapse-related symptoms. Conse-
quently, while time to progression confirmed at 3 or
6 months may be standard within the relatively short
timeframe of clinical trials, these outcomes may not cap-
ture the true accumulation of MS-related disability over
the lifecourse, and thus true differences between DMTs
in delaying disease progression.
NMA models also had imbalanced risk of bias across
the networks of studies. For example, most trials com-
paring two active treatments were open-label, whereas
most trials comparing active treatments against placebos
were blinded. Many trials relied on short follow-up, gen-
erally less than two years in duration, which increases
the risk of spurious results [21]. Thus, participants were
aware of the drugs they were receiving. This might have
posed a greater risk for unblinding of outcome assessors
than in ostensibly double-blinded trials. In addition, the
majority of studies were judged as high risk of bias
under the ‘other’ category of the Cochrane tool given
that most of these were funded by drug companies.
Although no research has specifically been undertaken
in the field of MS trials, empirical examination of trials
suggests that industry-sponsored RCTs are more likely
to have favourable results than non-industry sponsored
RCTs [2]. A final issue is that patient populations
recruited into trials may not be the same over time,
given the nearly 20-year span of the trials included in
our models. These differences may well extend to diag-
nostic definitions of MS, and detection and diagnosis of
relapses and disease progression. Again, insufficient stud-
ies on each pairwise comparison prevented exploration of
this problem, but it is conceivable that this might have
affected transitivity of our networks of evidence.
Review-level strengths and limitations
We used a rigorous and exhaustive search to locate pri-
mary studies, which included updating existing
high-quality systematic reviews. Additionally we used
auditable and transparent methods to include and syn-
thesise studies. Where appropriate, we undertook post
hoc sensitivity analyses in our clinical effectiveness
assessments to check the robustness of our findings.
However, a limitation of our work, inherent to all sys-
tematic reviews, is publication bias. Methods for detect-
ing publication bias in NMAs are still in development,
and we did not have enough studies in any one
TTP3: GA 20 mg SC daily vs. Placebo
Bornstein 1987
Cop1 MSSG 1995
CONFIRM 2012
Subtotal  (I−squared = 31.7%, p = 0.231)
TTP3: IFN β−1a 30 μg IM weekly vs. Placebo
BRAVO 2014
Subtotal  (I−squared = .%, p = .)
TTP3: IFN β−1a 44 μg SC thrice weekly vs. Placebo
PRISMS 1998
Subtotal  (I−squared = .%, p = .)
TTP3: IFN β−1a 22 μg SC thrice weekly vs. Placebo
PRISMS 1998
Subtotal  (I−squared = .%, p = .)
TTP3: IFN β−1a pegylated 125 μg SC every 2 weeks vs. Placebo
ADVANCE 2014
Subtotal  (I−squared = .%, p = .)
TTP3: IFN β−1b 250 μg SC every other day vs. Placebo
IFNB MSSG 1995
Subtotal  (I−squared = .%, p = .)
TTP3: IFN β−1a 44 μg SC thrice weekly vs. IFN β−1a 22 μg SC thrice weekly
PRISMS 1998
Subtotal  (I−squared = .%, p = .)
TTP3: IFN β−1a 44 μg SC thrice weekly vs. IFN β−1a 30 μg IM weekly
EVIDENCE 2007
Subtotal  (I−squared = .%, p = .)
TTP3: IFN β−1b 250 μg SC every other day vs. GA 20 mg SC daily
BEYOND 2009
Subtotal  (I−squared = .%, p = .)
TTP6: GA 20 mg SC daily vs. Placebo
CONFIRM 2012
Subtotal  (I−squared = .%, p = .)
TTP6: IFN β−1a 30 μg IM weekly vs. Placebo
MSCRG 1996
BRAVO 2014
Subtotal  (I−squared = 0.0%, p = 0.472)
TTP6: IFN β−1a pegylated 125 μg SC every 2 weeks vs. Placebo
ADVANCE 2014
Subtotal  (I−squared = .%, p = .)
TTP6: IFN β−1a 30 μg IM weekly vs. IFN β−1b 250 μg SC every other day
INCOMIN 2002
Subtotal  (I−squared = .%, p = .)
TTP6: IFN β−1a 44 μg SC thrice weekly vs. IFN β−1a 30 μg IM weekly
EVIDENCE 2007
Subtotal  (I−squared = .%, p = .)
TTP6: IFN β−1b 250 μg SC every other day vs. GA 20 mg SC daily
BECOME 2009
Subtotal  (I−squared = .%, p = .)
Study
0.37 (0.14, 1.00)
0.76 (0.50, 1.16)
0.93 (0.63, 1.37)
0.79 (0.60, 1.05)
0.74 (0.51, 1.08)
0.74 (0.51, 1.08)
0.62 (0.43, 0.90)
0.62 (0.43, 0.90)
0.68 (0.48, 0.97)
0.68 (0.48, 0.97)
0.62 (0.40, 0.97)
0.62 (0.40, 0.97)
0.71 (0.48, 1.06)
0.71 (0.48, 1.06)
0.91 (0.63, 1.32)
0.91 (0.63, 1.32)
0.87 (0.58, 1.31)
0.87 (0.58, 1.31)
1.06 (0.81, 1.37)
1.06 (0.81, 1.37)
0.87 (0.55, 1.38)
0.87 (0.55, 1.38)
0.57 (0.34, 0.95)
0.73 (0.47, 1.14)
0.66 (0.47, 0.92)
0.46 (0.26, 0.81)
0.46 (0.26, 0.81)
2.24 (1.21, 4.12)
2.24 (1.21, 4.12)
0.70 (0.39, 1.25)
0.70 (0.39, 1.25)
0.66 (0.19, 2.28)
0.66 (0.19, 2.28)
ratio (95% CI)
Hazard
Favours treatment 1 Favours treatment 2 
1.25 .5 2
Fig. 3 Pairwise meta-analyses for time to progression. IFN: interferon, GA: glatiramer acetate, IM: intramuscular, SC: subcutaneous; TTP3: time to
progression confirmed at 3 months; TTP6: time to progression confirmed at 6 months
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comparison to test for small-study bias. This may be es-
pecially relevant since many of the early trials of IFN
and GA for MS were small trials. Another important
limitation was the selective and inconsistent reporting of
outcomes. For example, one of the reasons we did not
undertake a meta-analysis of time to first relapse is that
there was inconsistent and often poor reporting, espe-
cially across multiple reports of the same study, which
prevented imputation of hazard ratios. We were also un-
able to obtain meta-analysable data for one study [12],
due to the tight timeline within which the original work
was undertaken.
Our analysis methods had a number of statistical ad-
vantages as well as some limitations. In examining the
effect of IFN and GA on progression, we used time to
event outcomes and hazard ratios instead of calculating
risk ratios or odds ratios at different follow-up points.
Thus, trial findings were reported at their fullest ‘matur-
ity’ [22] and all relevant data were included. We were
unable to verify empirically whether hazard ratios and
Table 4 Network meta-analysis results for time to progressiona
Time to progression confirmed at 3 months
Drug SUCRA IFN β-1a 44 μg
SC thrice
weekly
PegIFN β-1a
125 μg every
2 weeks
IFN β-1a
22 μg SC
thrice weekly
IFN β-1a
30 μg IM
weekly
GA
20 mg
daily
IFN β-1b
250 μg SC every
other day
Placebo GA 40 mg
SC thrice
weekly
IFN β-1a 44 μg
SC thrice
weekly
0.77 1.01 (0.59, 1.74) 0.92 (0.65,
1.30)
0.86 (0.62,
1.19)
0.82
(0.56,
1.22)
0.81 (0.53, 1.22) 0.63 (0.46, 0.86) Not
included in
this analysis
PegIFN β-1a
125 μg every
2 weeks
0.75 0.91 (0.52,
1.59)
0.85 (0.49,
1.46)
0.81
(0.49,
1.34)
0.80 (0.47, 1.34) 0.62 (0.40, 0.97)
IFN β-1a 22 μg
SC thrice
weekly
0.62 0.94 (0.62,
1.42)
0.90
(0.59,
1.36)
0.88 (0.57, 1.36) 0.68 (0.49, 0.96)
IFN β-1a 30 μg
IM weekly
0.5 0.96
(0.65,
1.42)
0.94 (0.62, 1.43) 0.73 (0.53,
1.00)*
GA 20 mg daily 0.44 0.98 (0.78, 1.24) 0.76 (0.60, 0.97)
IFN β-1b
250 μg SC every
other day
0.39 0.78 (0.59, 1.02)
Placebo 0.02
Test for inconsistency
(χ2, df, p)
0.35, 2, 0.84
Time to progression confirmed at 6 months
Drug SUCRA IFN β-1b
250 μg SC every
other day
PegIFN β-1a
125 μg every
2 weeks
IFN β-1a
44 μg SC
thrice weekly
IFN β-1a
30 μg IM
weekly
GA
20 mg
daily
Placebo PegIFN β-1a
125 μg every
2 weeks
GA 40 mg
thrice
weekly
IFN β-1b
250 μg SC every
other day
0.9 0.74 (0.32, 1.71) 0.71 (0.32,
1.60)
0.50 (0.29,
0.87)
0.42
(0.21,
0.83)
0.34 (0.18, 0.63) Not included in this analysis
PegIFN β-1a
125 μg every
2 weeks
0.71 0.97 (0.40,
2.33)
0.68 (0.35,
1.31)
0.56
(0.28,
1.15)
0.46 (0.26, 0.81)
IFN β-1a 44 μg
SC thrice
weekly
0.7 0.70 (0.39,
1.25)
0.58
(0.27,
1.27)
0.47 (0.24, 0.93)
IFN β-1a 30 μg
IM weekly
0.4 0.83
(0.49,
1.41)
0.68 (0.49, 0.94)
GA 20 mg daily 0.25 0.82 (0.53, 1.26)
Placebo 0.05
Test for inconsistency
(χ2, df, p)
0.77, 1, 0.38
aFindings are presented as HR (95% CI)
IFN interferon, GA glatiramer acetate, IM intramuscular, SC subcutaneous, SUCRA surface under the cumulative ranking curve
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rate ratios were time-varying due to few comparisons on
every node of the study networks. On the other hand,
we judged that stratifying analyses by time to follow-up
would have resulted in excessively sparse networks that
would have been difficult to interpret collectively. Thus,
our decision to pool study estimates across follow-up
times for analyses of clinical outcomes was both a
strength and a potential limitation. Notably, we stratified
analyses by time to follow-up in NMAs of discontinua-
tions due to AEs, because we judged that the only feas-
ible estimator in these analyses was the risk ratio.
Deviations from protocol
In our protocol, we specified that the comparator of
interest was best supportive care without DMTs. In
practice, this includes both best supportive care and also
placebo, as reported in included trials. Though we
sought to examine 10 outcomes relevant to RRMS in
our original protocol, we report here findings for relapse
rate, disability and discontinuation due to adverse
events, as synthesis for other outcomes was limited and
in many parts meta-analysable. Detailed findings for
each of these outcomes are available in the main report
[2]. Moreover, disability was ultimately measured and
included in these meta-analyses as ‘time to progression’,
as this was the most common outcome across trials.
Finally, we implemented network meta-analyses in a
frequentist paradigm rather than using WinBUGS as
specified in the protocol.
In relation to research and practice
Our findings updated prior reviews, though comparabil-
ity of findings is limited. We included trials examining
IFN and GA against each other and against a
no-treatment comparator, and restricted inclusion to
doses and formulations within their marketing author-
isation as compared to Tramacere et al. [3] who broadly
examined immunomodulators and immunosuppressants
for RRMS. Because they included studies across drugs
and because they used risk ratios as the sole outcome
estimator, our analyses and theirs are largely incommen-
surate. Our systematic review and NMA may however
offer more clinically relevant evidence because of our
focus on doses used in clinical practice. However, our
analyses for discontinuation due to AEs agreed with
theirs. Neither review suggested that any one drug had a
significant effect on discontinuation due to AEs relative
to placebo.
Our findings agree with the ABN guidelines [1] in that
the guidelines classify IFN-β and GA as drugs of ‘moder-
ate efficacy’, and observe that there is not much data to
support differences in effectiveness between them. Our
analysis does suggest that these drugs are effective in
reducing relapse rate, which may have an effect on
progression.
Longer-term observational cohorts have also examined
DMT effectiveness over time and shed some doubt on
the findings from randomised trials. In the year 8 ana-
lyses from the UK Risk Sharing Scheme, DMTs were not
found to be cost-effective and the drugs assessed were
not substantially different in terms of delays in disease
progression (personal communication with UK Depart-
ment of Health, 2016). An analysis from the MSBase
study, an international registry with ‘real-world’ data
from MS patients, has suggested that GA or subcutane-
ous IFN-β-1a are more effective in controlling relapse
rate than other IFN-β, though drugs were not different
on disease progression [23]. While this analysis relied on
matching to overcome lack of randomisation, a strength
is that it used disability progression confirmed at
12 months instead of at 3 or 6 months.
Future research
First, findings from this review will require updating as
generic versions of the DMTs considered here are
authorised. For example, the GATE trial also tested a
generic version of glatiramer acetate against the branded
version and placebo [24]. Key flaws in the assembled
clinical effectiveness evidence included the lack of
long-term follow-up and the absence of a measure for
disease progression adequately capturing worsening of
disability. A large-scale, longitudinal randomised trial
comparing active first-line agents and using clinically
meaningful and robust measures of disability progres-
sion would contribute towards resolving uncertainty
about the relative benefits of different IFN or GA formu-
lations (and other first line agents). While other, newer
first line agents were beyond the remit of our systematic
review, few randomised comparisons exist and thus a
large trial could resolve remaining questions of com-
parative effectiveness. It may also be that using standar-
dised definitions for relapses and disease progression
together with blinded adjudicator panels could attenuate
the risk of bias accruing to an open-label trial. Because
of this lack of long-term follow-up, DMT trials are not
informative on whether drugs delay progression to
SPMS. Understanding long-term effectiveness of DMTs
as described above would will also provide better infor-
mation for informing cost-effectiveness evaluations, the
effectiveness estimates for which currently rely on
extrapolation from short-term trials. Use of a more rele-
vant measure for disability and disease progression,
especially as regards the development of secondary pro-
gressive MS, will also lead to better and more robust
valuation of benefits accruing from DMTs.
Finally, above and beyond the broad interpretation
that DMTs reduce ARR, there is a need to understand
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who responds best to DMTs; especially who does not
respond to IFN or GA early on, to enable more targeted
therapeutic decisions. Though several trials included in
our clinical effectiveness review used subgroup analyses,
based for example, on presenting lesions or demographic
characteristics, a more fine-grained understanding can
help patients and clinicians make better-informed
decisions.
Conclusions
Our meta-analyses confirmed that IFN-β and GA reduce
ARR and generally delay progression as defined in these
trials. We found, however, that there was no clear ‘win-
ner’ across outcomes, and our findings were qualified by
the high risk of bias across studies, and the use of an
impairment/mobility scale to measure disease progres-
sion. Future research should consider more relevant
measures of disability and, given that most trials have
been short-term, consider a longitudinal approach to
comparative effectiveness.
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